Clot Buster Drugs Market is expected to grow at a CAGR of 7.71% through 2031
Global Clot Buster Drugs Market is driven by increasing
heart disease instances in the forecast period, 2027-2031F.
According to TechSci Research report, “Clot
Buster Drugs Market - Global Industry Size, Share, Trends, Opportunity and
Forecast, 2021-2031F”, the Global Clot Buster Drugs Market will grow from USD 35.72 Billion in 2025 to USD 55.78 Billion by 2031 at a 7.71% CAGR,
on account of increasing instances of cardiovascular diseases. Increasing mortality rate due to patients suffering from heart attacks and strokes is further driving the growth of the global clot-buster drugs market in the upcoming five years.
Additionally, increasing demand for pharmaceutical products used as an immediate response to heart attacks and strokes further supports the growth of the global clot-buster drugs market over the next five years. The growth of the pharmaceutical industry and the development of clot-busting therapeutic products further support the global clot-buster drugs market over the next five years.
Increasing demand for more efficient and effective treatment and pharmaceuticals for the surging cases of strokes, such as ischemic strokes, is further anticipated to aid the growth of the global clot buster drugs market in the forecast years, until 2031.
Growing research, technological development, and investment are additional factors driving the growth of the global clot-buster drugs market over the forecast period. Although, increasing awareness among the
population toward precautions and monitoring their diet, habits, etc. to improve
their quality of life may slow down the demand for clot buster drugs and thus
affect the growth of the global clot buster drugs market in the upcoming five
years.
Browse over XX
market data Figures spread through 110 Pages
and an in-depth TOC on "Global Clot Buster Drugs Market"
https://www.techsciresearch.com/report/clot-buster-drugs-market/8207.html
The global clot-buster drugs market is segmented by type,
application, distribution channel, regional distribution, and competitive
landscape. Based on type, the market is divided between fibrin-specific drugs and non-fibrin-specific drugs. Further segmentation of fibrin-specific drugs is defined into tissue plasminogen activator, Reteplase, Tenecteplase, and others.
Fibrin-specific drugs are fibrinolysis-causing agents that do not have any significant lytic actions but act as a blood-dissolving agent during stroke conditions. These drugs include tissue plasminogen activator (tPA), which initiates the dissolution of blood clots in stroke. The drug is quite
risky and requires monitored administration since side effects include slurred
speech, immobility or brain damage in adverse situations.
Non-fibrin-specific drugs are classified into urokinase, streptokinase, and plasminogen-activating complex. Urokinase is a serine protease used to treat blood clots in the lungs. Streptokinase is a thrombolytic drug used in cases of myocardial infarction, pulmonary embolism, and arterial thromboembolism.
Based on application, the market is further segmented into myocardial
infarction, pulmonary embolism, deep vein thrombosis, acute ischemic stroke, and other indications. Acute ischemic strokes are anticipated to hold the most significant revenue
shares and dominate the market segment in the upcoming five years on account of increasing cases of ischemic strokes among the global population. In
2017, 82.42 million cases were registered globally of the population that
suffered from ischemic strokes.
Some of the market players, dominating the global market are:
- Genentech Inc.
- Dr. Reddy’s Laboratories
- Bayer AG
- Eli Lilly and Company
- Pfizer Inc.
- Johnson & Johnson Services Inc
- Sun Pharmaceutical Industries Ltd.
- Boehringer Ingelheim Gmbh
- Sanofi
- Merck & Co
The existing market players
are highly invested in research and product development along with viable
service provisions for the consumers. New market entrants may adopt similar strategies, including mergers and acquisitions, to establish the brand.
Download Sample Report @
https://www.techsciresearch.com/sample-report.aspx?cid=8207
Customers can also request for 10% free customization on this report.
“North America is anticipated to dominate the regional distribution of the global clot buster drugs market in the upcoming five years due to increasing instances of cardiovascular diseases in countries like the United States, Canada, etc. The surge in demand for clot-busting drugs as an immediate response to heart attacks and strokes, along with the increasing incidence of these events, is driving growth in the global clot-buster drugs market over the next five years. Sedentary lifestyle and increasing
instances of lifestyle diseases like diabetes, high cholesterol levels,
obesity, and high blood pressure further increase the chances of strokes thus
aiding to the growth of the global clot buster drugs market in the future five
years. Patients at risk of heart attacks and are already suffering from severe heart conditions need to monitor their situations and, in the emergency circumstance of stroke, are required to administer clot-buster drugs within 90 minutes of the stroke episode. Increasing concerns and patient awareness is
also aiding the growth of the global clot buster drugs market in the forecast
years. New market players may form partnerships with the global pharmaceutical giants for their future brand establishments,” said Mr Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.
“Clot Buster Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Type (Fibrin Specific Drugs {Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others} v/s Non-Fibrin Specific Drugs {Urokinase, Streptokinase, Plasminogen Activating Complex}), By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region 2021-2031F”,
has evaluated the future growth potential of global clot buster drugs and
provides statistics & information on market size, structure and future
market growth. The report aims to provide cutting-edge market intelligence and help decision-makers make sound investment decisions. Besides, the report also identifies and analyses the emerging trends along with essential drivers, challenges, and opportunities in the global clot buster drugs market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/